ENTITY
Grifols

Grifols (GRFS US)

30
Analysis
Health CareSpain
Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.
more
bullishGrifols SA
16 Apr 2025 18:43

Liquid Universe of European Ordinary and Preferred Shares: April '25 Report

Since mid-March, with sessions of massive volatility, share-price spreads have generally tightened across European liquid universe of ordinary and...

Share
bullishGrifols SA
03 Apr 2025 05:30

Blood, Sweat, and Bids: Grifols Draws Renewed Interest from Brookfield

​Brookfield's renewed interest in Grifols signals confidence in its turnaround, with strengthened financials and potential for improved future...

Share
17 Mar 2025 06:45

Liquid Universe of European Ordinary and Preferred Shares: March '25 Report

​European share-price spreads have generally tightened since mid-February, with volatility; Carlsberg B discount at 5-year record low,...

Share
17 Feb 2025 07:12

Liquid Universe of European Ordinary and Preferred Shares: February'25 Report

Since mid-January, share-price spreads have generally widened across European liquid universe of ordinary and preferred shares (11 have widened, 3...

Share
bullishCSL Ltd
12 Feb 2025 08:30

CSL Ltd (CSL AU): Weak Vaccine Sales Affect H1FY25 Performance; FY25 Guidance Maintained

​CSL Ltd's H1FY25 net profit rises 6% YoY to $2.01B, missing estimates. Revenue is up 5% YoY to $8.48B. FY25 profit guidance reaffirmed at $3.2...

Logo
335 Views
Share
x